Fighting Cancer

Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • vb-400x210

    Vigilant Biosciences’ Scientific Founder and Chief Scientific Officer, Elizabeth Franzmann, M.D., is Honored by Greater Miami Chamber of Commerce with 2016 Health Care Heroes® Award

    Dr. Franzmann Honored for Dedication to Oral Cancer Research and Prevention FORT LAUDERDALE, Fla. – May 17, 2016 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer,…more

  • dentistryIQ

    Vigilant Biosciences receives CE mark for OncAlert Oral Cancer Rapid Test

    The CE mark, a mandatory conformity marking in the European Union (EU), will allow the product to be sold in the 28 countries of the EU and Norway, Iceland, Liechtenstein and Switzerland. Vigilant Biosciences Inc. has announced that it has…more

  • Screen Shot 2015-09-08 at 12.56.25 PM

    Vigilant Biosciences Receives CE Mark for OncAlert Oral Cancer RAPID Test

    Vigilant Biosciences, a developer of solutions that aid in the early detection and intervention of cancer, has announced that it has CE Marked its OncAlert Oral Cancer RAPID Test. CE Marking allows Vigilant Biosciences to market the product in the…more

  • miami-herald_logo2

    Vigilant Biosciences cleared to launch its oral cancer test across Europe

    Vigilant Biosciences, an early-stage Fort Lauderdale-based company that develops solutions that aid in the early detection and intervention of cancer, announced that it has CE Marked its OncAlert Oral Cancer RAPID Test, meaning it can market the product in the…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×